{"success":true,"data":{"pressRelease":{"id":"154622","rtpr_id":"nNFCbbBxFl-20260928","ticker":"PREV","exchange":"","all_tickers":["PREV"],"title":"PreveCeutical Announces Non-Brokered Private Placement","author":"Newsfile Corp","published_at":"2026-09-28T21:00:09.390Z","article_body":"Vancouver, British Columbia--(Newsfile Corp. - September 28, 2026) -\nPreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the\n\"Company\" or \"PreveCeutical\"), is pleased to announce a non-brokered private\nplacement (the \"Offering\") of up to 20,000,000 units (each, a \"Unit\") in the\ncapital of the Company at a price of $0.03 per Unit for gross proceeds of up\nto $600,000. Each Unit consists of one (1) common share of the Company (each,\na \"Share\") and one-half (1/2) of one Share purchase warrant (each whole\nwarrant, a \"Warrant\"). Each Warrant entitles the holder thereof to purchase an\nadditional Share (each, a \"Warrant Share\") at an exercise price of $0.06 per\nWarrant Share for a period of two years from the closing of the Offering (the\n\"Closing\"); provided that the expiry of the Warrants can be accelerated if the\nclosing price of the Company's common shares on the Canadian Securities\nExchange (the \"CSE\") is $0.11 or greater for a minimum of ten consecutive\ntrading days, and a notice of acceleration is provided in accordance with the\nterms of the Warrants.\n\nFinder's fees may be paid in connection with the Offering. The Company intends\nto use the aggregate gross proceeds from the sale of the Offering for short\nloan repayments, audit, accounting and legal fees, patents and further studies\nand analysis of rodents and tissues and general working capital purposes.\n\nAll securities issued in connection with the Offering will be subject to a\nstatutory hold period expiring four months and one day after the Closing.\nCompletion of the Offering remains subject to certain conditions, including,\nwithout limitation, confirmation of no objection from the CSE.\n\nThe securities issued under the Offering will not be registered under the\nUnited States Securities Act of 1933, as amended (the \"Securities Act\"), and\nmay not be offered or sold in the United States absent registration or an\napplicable exemption from the registration requirements under the Securities\nAct. This news release shall not constitute an offer to sell or the\nsolicitation of an offer to buy nor shall there be any sale of the securities\nin any jurisdiction in which such offer, solicitation or sale would be\nunlawful.\n\nAbout PreveCeutical\n\nPreveCeutical is a health sciences company that develops innovative options\nfor preventive and curative therapies utilizing organic and nature identical\nproducts. PreveCeutical aims to be a leader in preventive health sciences and\ncurrently has five research and development programs, including: dual gene\ntherapy for curative and prevention therapies for diabetes and obesity; the\nSol-gel Program; Nature Identical™ peptides for treatment of various\nailments; nonaddictive analgesic peptides as a replacement to the highly\naddictive analgesics such as morphine, fentanyl and oxycodone; and a\ntherapeutic product for treating athletes who suffer from concussions (mild\ntraumatic brain injury). For more information about PreveCeutical, please\nvisit our website www.PreveCeutical.com or follow us on Twitter\n(https://api.newsfilecorp.com/redirect/DOk8etYzPr) and Facebook\n(https://api.newsfilecorp.com/redirect/rpMzDta8wk).\n\nOn behalf of the Board of Directors of PreveCeutical \nStephen Van Deventer, Chairman and Chief Executive Officer \n\nFor further information, please contact:\n\nStephen Van Deventer: +1 604 306 9669 \nOr Investor Relations \nir@preveceutical.com\n\nNeither the CSE nor any Market Regulator (as that term is defined in the\npolicies of the CSE) accepts responsibility for the adequacy or accuracy of\nthis release.\n\nForward-Looking Statements:\n\nThis news release includes certain \"forward-looking statements\" under\napplicable Canadian securities legislation that are not historical facts.\nForward-looking statements involve risks, uncertainties, and other factors\nthat could cause actual results, performance, prospects, and opportunities to\ndiffer materially from those expressed or implied by such forward-looking\nstatements. Forward-looking statements in this news release include, but are\nnot limited to, statements with respect to the expectations of management\nregarding the proposed Offering, the expectations of management regarding the\nuse of proceeds of the Offering, closing conditions for the Offering, the\nexpiry of hold periods for securities distributed pursuant to the Offering and\nother statements regarding the company's proposed business plans. Although the\nCompany believes that the expectations reflected in the forward-looking\ninformation are reasonable, there can be no assurance that such expectations\nwill prove to be correct. Such forward-looking statements are subject to risks\nand uncertainties that may cause actual results, performance or developments\nto differ materially from those contained in the statements including that:\nthe Company may not complete the Offering on terms favorable to the Company or\nat all; the proceeds of the Offering may not be used as stated in this news\nrelease; the Company may be unable to satisfy all of the conditions to the\nClosing; and those additional risks set out in the Company's public documents\nfiled on SEDAR+ at www.sedarplus.ca. Although the Company believes that the\nassumptions and factors used in preparing the forward-looking statements are\nreasonable, undue reliance should not be placed on these statements, which\nonly apply as of the date of this news release, and no assurance can be given\nthat such events will occur in the disclosed time frames or at all. Except\nwhere required by law, the Company disclaims any intention or obligation to\nupdate or revise any forward-looking statement, whether as a result of new\ninformation, future events, or otherwise.\n\nNOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION\nIN THE UNITED STATES\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316382","article_body_html":"","raw_payload":{"data":{"id":"nNFCbbBxFl-20260928","title":"PreveCeutical Announces Non-Brokered Private Placement","author":"Newsfile Corp","ticker":"PREV","created":"2026-09-28T21:00:09.390Z","tickers":["PREV"],"exchange":"","article_body":"Vancouver, British Columbia--(Newsfile Corp. - September 28, 2026) -\nPreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the\n\"Company\" or \"PreveCeutical\"), is pleased to announce a non-brokered private\nplacement (the \"Offering\") of up to 20,000,000 units (each, a \"Unit\") in the\ncapital of the Company at a price of $0.03 per Unit for gross proceeds of up\nto $600,000. Each Unit consists of one (1) common share of the Company (each,\na \"Share\") and one-half (1/2) of one Share purchase warrant (each whole\nwarrant, a \"Warrant\"). Each Warrant entitles the holder thereof to purchase an\nadditional Share (each, a \"Warrant Share\") at an exercise price of $0.06 per\nWarrant Share for a period of two years from the closing of the Offering (the\n\"Closing\"); provided that the expiry of the Warrants can be accelerated if the\nclosing price of the Company's common shares on the Canadian Securities\nExchange (the \"CSE\") is $0.11 or greater for a minimum of ten consecutive\ntrading days, and a notice of acceleration is provided in accordance with the\nterms of the Warrants.\n\nFinder's fees may be paid in connection with the Offering. The Company intends\nto use the aggregate gross proceeds from the sale of the Offering for short\nloan repayments, audit, accounting and legal fees, patents and further studies\nand analysis of rodents and tissues and general working capital purposes.\n\nAll securities issued in connection with the Offering will be subject to a\nstatutory hold period expiring four months and one day after the Closing.\nCompletion of the Offering remains subject to certain conditions, including,\nwithout limitation, confirmation of no objection from the CSE.\n\nThe securities issued under the Offering will not be registered under the\nUnited States Securities Act of 1933, as amended (the \"Securities Act\"), and\nmay not be offered or sold in the United States absent registration or an\napplicable exemption from the registration requirements under the Securities\nAct. This news release shall not constitute an offer to sell or the\nsolicitation of an offer to buy nor shall there be any sale of the securities\nin any jurisdiction in which such offer, solicitation or sale would be\nunlawful.\n\nAbout PreveCeutical\n\nPreveCeutical is a health sciences company that develops innovative options\nfor preventive and curative therapies utilizing organic and nature identical\nproducts. PreveCeutical aims to be a leader in preventive health sciences and\ncurrently has five research and development programs, including: dual gene\ntherapy for curative and prevention therapies for diabetes and obesity; the\nSol-gel Program; Nature Identical™ peptides for treatment of various\nailments; nonaddictive analgesic peptides as a replacement to the highly\naddictive analgesics such as morphine, fentanyl and oxycodone; and a\ntherapeutic product for treating athletes who suffer from concussions (mild\ntraumatic brain injury). For more information about PreveCeutical, please\nvisit our website www.PreveCeutical.com or follow us on Twitter\n(https://api.newsfilecorp.com/redirect/DOk8etYzPr) and Facebook\n(https://api.newsfilecorp.com/redirect/rpMzDta8wk).\n\nOn behalf of the Board of Directors of PreveCeutical \nStephen Van Deventer, Chairman and Chief Executive Officer \n\nFor further information, please contact:\n\nStephen Van Deventer: +1 604 306 9669 \nOr Investor Relations \nir@preveceutical.com\n\nNeither the CSE nor any Market Regulator (as that term is defined in the\npolicies of the CSE) accepts responsibility for the adequacy or accuracy of\nthis release.\n\nForward-Looking Statements:\n\nThis news release includes certain \"forward-looking statements\" under\napplicable Canadian securities legislation that are not historical facts.\nForward-looking statements involve risks, uncertainties, and other factors\nthat could cause actual results, performance, prospects, and opportunities to\ndiffer materially from those expressed or implied by such forward-looking\nstatements. Forward-looking statements in this news release include, but are\nnot limited to, statements with respect to the expectations of management\nregarding the proposed Offering, the expectations of management regarding the\nuse of proceeds of the Offering, closing conditions for the Offering, the\nexpiry of hold periods for securities distributed pursuant to the Offering and\nother statements regarding the company's proposed business plans. Although the\nCompany believes that the expectations reflected in the forward-looking\ninformation are reasonable, there can be no assurance that such expectations\nwill prove to be correct. Such forward-looking statements are subject to risks\nand uncertainties that may cause actual results, performance or developments\nto differ materially from those contained in the statements including that:\nthe Company may not complete the Offering on terms favorable to the Company or\nat all; the proceeds of the Offering may not be used as stated in this news\nrelease; the Company may be unable to satisfy all of the conditions to the\nClosing; and those additional risks set out in the Company's public documents\nfiled on SEDAR+ at www.sedarplus.ca. Although the Company believes that the\nassumptions and factors used in preparing the forward-looking statements are\nreasonable, undue reliance should not be placed on these statements, which\nonly apply as of the date of this news release, and no assurance can be given\nthat such events will occur in the disclosed time frames or at all. Except\nwhere required by law, the Company disclaims any intention or obligation to\nupdate or revise any forward-looking statement, whether as a result of new\ninformation, future events, or otherwise.\n\nNOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION\nIN THE UNITED STATES\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316382"},"type":"article","timestamp":"2026-09-28T21:00:09.458760688Z","server_sent_at_ms":1790629209458},"received_at":"2026-09-28T21:00:09.527Z","source_url":"https://www.newsfilecorp.com/release/316382"},"analysis":{"id":"143382","press_release_id":"154622","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["proceeds partly used to repay short-term loans, signaling tight liquidity","dilutive penny-level financing with attached warrants (potential ~30M additional shares at $0.06)","completion subject to CSE non-objection"],"eventType":"offering","narrative":"PreveCeutical Medical announced a non-brokered private placement of up to 20 million units at $0.03 per unit for gross proceeds of up to $600,000.\n\nEach unit includes one share plus a half-warrant exercisable at $0.06 for two years, with acceleration if the CSE closing price reaches $0.11 for ten consecutive trading days.\n\nProceeds are earmarked for short-term loan repayments, audit and legal fees, patents, R&D, and working capital -- a small but dilutive raise for a pre-revenue health sciences micro-cap.","sentiment":"bearish","agentHooks":{"shouldPost":false,"suggestedAngle":"Micro-cap dilutive raise with loan repayment in use of proceeds -- monitor liquidity."},"keyFigures":{"dealValueUsd":600000,"offeringPrice":0.03,"sharesOffered":20000000,"customDimensions":{"hold_period":"four months and one day","warrant_term":"two years","warrant_coverage":"one-half warrant per unit","acceleration_trigger":"$0.11 or greater for 10 consecutive trading days","warrant_exercise_price":0.06}},"namedEntities":{"people":[{"name":"Stephen Van Deventer","role":"Chairman and CEO"}],"products":["Sol-gel Program","Nature Identical™ peptides"],"companies":[{"name":"PreveCeutical Medical Inc.","ticker":"PREV"},{"name":"Canadian Securities Exchange","relationship":"exchange/regulator"}],"dollarAmounts":[{"amount":"$600,000","context":"maximum gross proceeds of private placement"},{"amount":"$0.03","context":"price per Unit"},{"amount":"$0.06","context":"warrant exercise price per share"},{"amount":"$0.11","context":"warrant acceleration trigger price"}]},"materialImpact":{"score":2,"reasoning":"Micro-cap non-brokered private placement raising up to $600,000 at $0.03 per unit with half-warrants -- small but dilutive financing at penny-stock levels. Use of proceeds includes repaying short-term loans, signaling tight liquidity."},"tickerRelevance":{"others":[],"primary":"PREV"},"globalImportance":8,"audienceRelevance":5,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"small private placement","dilutionSignal":"warrants plus penny pricing"}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bearish","material_impact_score":2,"narrative":"PreveCeutical Medical announced a non-brokered private placement of up to 20 million units at $0.03 per unit for gross proceeds of up to $600,000.\n\nEach unit includes one share plus a half-warrant exercisable at $0.06 for two years, with acceleration if the CSE closing price reaches $0.11 for ten consecutive trading days.\n\nProceeds are earmarked for short-term loan repayments, audit and legal fees, patents, R&D, and working capital -- a small but dilutive raise for a pre-revenue health sciences micro-cap.","key_figures":{"dealValueUsd":600000,"offeringPrice":0.03,"sharesOffered":20000000,"customDimensions":{"hold_period":"four months and one day","warrant_term":"two years","warrant_coverage":"one-half warrant per unit","acceleration_trigger":"$0.11 or greater for 10 consecutive trading days","warrant_exercise_price":0.06}},"named_entities":{"people":[{"name":"Stephen Van Deventer","role":"Chairman and CEO"}],"products":["Sol-gel Program","Nature Identical™ peptides"],"companies":[{"name":"PreveCeutical Medical Inc.","ticker":"PREV"},{"name":"Canadian Securities Exchange","relationship":"exchange/regulator"}],"dollarAmounts":[{"amount":"$600,000","context":"maximum gross proceeds of private placement"},{"amount":"$0.03","context":"price per Unit"},{"amount":"$0.06","context":"warrant exercise price per share"},{"amount":"$0.11","context":"warrant acceleration trigger price"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-28T21:00:14.995Z","global_importance":8,"audience_relevance":5,"importance_components":{"tickerTier":"micro-cap","eventGravity":"small private placement","dilutionSignal":"warrants plus penny pricing"}},"durationMs":5457,"modelName":"glm-5.3-flashx"}}